Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

New Episode Looks At Drug, Vaccine Development

Executive Summary

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Featuring Brian Yang in Beijing, Vibha Ravi in Mumbai, Jung Won Shin in Seoul and Ian Haydock in Tokyo.

Topics covered include how local and foreign pharma firms in China are working to progress novel antivirals and how traditional medicines have found a role in the outbreak, Indian companies’ concerns over potential disruptions to API supplies from main supplier China, South Korean moves to address a spike in cases, and Japanese and multinational firms’ response. Also touching on what the impact might be on future R&D strategy.

01:30: China’s drug development efforts looking at antivirals, vaccines and TCMs.

07:20: India’s bulk supply concerns and what the industry is considering to diversify risk.

13:15: South Korea’s pharma industry and government are taking measured steps as the outbreak surges locally.

16:15: Japan’s pharma firms do not appear too concerned so far amid low exposure to China, while multinationals play wait and see over business impact/response.

(Rolling coverage of the outbreak and the biopharma industry's response is aggregated here.)

 

 

Topics

UsernamePublicRestriction

Register

SC141733

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel